Skip to main content

Regulatory announcement no 16: Reporting of transactions made by persons discharging managerial responsibilities and their closely associated persons in InstallatørGruppen’s shares

Reporting of transactions made by persons discharging managerial responsibilities and their closely associated persons in InstallatørGruppen’s shares Pursuant to the Market Abuse Regulation (EU) no. 596/2014, as amended, article 19, InstallatørGruppen A/S (“InstallatørGruppen”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in InstallatørGruppen and their closely associated persons in InstallatørGruppen’s shares. Reference is made to company announcement no. 14 – 2026 dated 10 July 2026 related to the end of the stabilisation period in connection with the initial public offering (the “Offering”) and admission to trading of the shares of InstallatørGruppen, and company announcement no. 15 – 2026 dated 10 July 2026 related to the partial exercise of the overallotment...

Continue reading

Haoxi Health Technology Ltd Announces $4 Million Registered Direct Offering

BEIJING, July 10, 2026 (GLOBE NEWSWIRE) — Haoxi Health Technology Ltd (NASDAQ: HAO) (“Haoxi” or the “Company”), today announced that it has entered into a definitive agreement with certain investors for the purchase and sale of an aggregate of 10,000,000 of the Company’s Class A Ordinary Shares, par value $0.32 per share (the “Shares”) (or pre-funded warrants in lieu thereof) at a purchase price of $0.40 per share in a registered direct offering. The purchase price for the pre-funded warrants is identical to the purchase price for Shares, less the exercise price of $0.33 per share. The aggregate gross proceeds to the Company of this offering are expected to be approximately $4 million. The transaction is expected to close on or about July 13, 2026, subject to the satisfaction of customary closing conditions. Univest Securities,...

Continue reading

Toll Brothers Announces New Luxury Home Community Coming Soon to Thousand Oaks, California

Mountain View Estates will offer 10 expansive home sites and exceptional home designs in a sought-after Southern California location THOUSAND OAKS, Calif., July 10, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest community, Mountain View Estates, is coming soon to Thousand Oaks, California. This exclusive enclave of just 10 expansive home sites is anticipated to open for sale in early 2027. Mountain View Estates will provide home shoppers with a rare opportunity to own a luxury home in one of Southern California’s most desirable locations. These striking two-story homes will offer over 3,600 square feet of living space, featuring bright, open-concept gathering areas, 5 bedrooms, 5.5 bathrooms, and 2- to 3-car garages. Detached casita options will also...

Continue reading

Regulatory announcement no 15: Partial exercise of overallotment option in connection with the initial public offering of InstallatørGruppen A/S

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular, or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017, as amended (the “Prospectus Regulation”) and nothing herein shall be construed as an offering of securities. The offer to acquire securities pursuant to the offering of shares in InstallatørGruppen A/S (“InstallatørGruppen” or the “Company”) will be made, and any investment decision by an investor should be made, solely on the basis of information that is contained in the offering circular or prospectus, which is made generally available in Denmark in connection with the...

Continue reading

Regulatory announcement no 14: End of stabilisation period

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL This announcement does not constitute an offering circular, or a prospectus as defined by Regulation (EU) No. 2017/1129 of 14 June 2017, as amended (the “Prospectus Regulation”) and nothing herein shall be construed as an offering of securities. The offer to acquire securities pursuant to the offering of shares in InstallatørGruppen A/S (“InstallatørGruppen” or the “Company”) will be made, and any investment decision by an investor should be made, solely on the basis of information that is contained in the offering circular or prospectus, which is made generally available in Denmark in connection with the...

Continue reading

Malaga Financial Corporation Reports Earnings for the First Six Months of 2026

PALOS VERDES ESTATES, Calif., July 10, 2026 (GLOBE NEWSWIRE) — Malaga Financial Corporation “Company” (OTCIQ:MLGF), the parent company of Malaga Bank FSB, today reported that net income for the six months ended June 30, 2026, was $11,758,000 ($1.19 basic and fully diluted earnings per share) compared to $10,950,000 ($1.11 basic and fully diluted earnings per share, as adjusted for the stock dividend declared on November 14, 2025) for the same period ended June 30, 2025. For the first six months of 2026, the Company’s annualized return on average equity was 10.37% and the annualized return on average assets was 1.63%. Book value per share stood at $23.21 as of June 30, 2026. The $808,000 increase in net income was primarily due to a $1,205,000 increase in net interest income after provision for loan losses, a $307,000 identity fraud...

Continue reading

AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM, SUSPENDING SOME NON-PRIORITY CLINICAL TRIALS TO FOCUS ON TWO CLINICAL PROGRAMS Paris, July 10, 2026, 6pm CET AB Science SA (Euronext – FR0010557264 – AB) today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for acute myeloid leukemia and the masitinib program for amyotrophic lateral sclerosis. Following the company’s press release dated April 16 [1], three clinical studies—which the company currently considers non-priority and for which patient enrollment had been suspended—are being discontinued, namely:Phase 2 study (AB20006) of masitinib in mast cell activation syndrome Phase 3 study (AB15003) of masitinib in...

Continue reading

Information relating to the total number of voting rights and share capital – June 30, 2026

Disclosure of the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the French Commercial Code and the Article 223-16 of the Règlement général de l’Autorité des marchés financiers   (Regulation of the French stock market authority) Company name of the issuer:         Renault S.A. 122 – 122 bis Avenue du Général Leclerc 92100 Boulogne-Billancourt (ISIN code: FR0000131906 – RNO)Date   Total number of issued shares     Total number of voting rightsJune 30, 2026     295,722,284     Theoretical number of voting rights(1): 405,495,739  Exercisable number of voting rights(2): 399,146,864(1)   Pursuant to Article 223-11 of the Règlement général de l’Autorité des marchés financiers, number calculated on the basis of all shares to which voting rights are attached, including shares for which...

Continue reading

Cosmos Health Launches Subscription Model

Subscription model already launched with NOOR Collagen in the United States Early data shows a repeat purchase rate above 60% at high margins in excess of 50% Model is designed to drive stronger loyalty, greater lifetime value, and more predictable cash-flow visibility Company plans to extend the subscription model to additional Cosmos Health products globally, with further initiatives already underwayCHICAGO, July 10, 2026 (GLOBE NEWSWIRE) — Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has launched a subscription-based purchasing model for its proprietary consumer health brands. The model is currently live with NOOR Collagen in the United States, with encouraging early results that include a repeat purchase...

Continue reading

Renault Group succeeds in England & Wales “Prohibited Defeat Devices” diesel emissions litigation

Press ReleaseJuly 10, 2026Renault Group succeeds in England & Wales “Prohibited Defeat Devices” diesel emissions litigation Finding in the Renault Group’s favour, the High Court of Justice has today handed down its liability judgment in the long running London diesel emissions litigation. In an extensive ruling, culminating years of proceedings involving thousands of pages of submissions, dozens of experts’ reports and witness statements, as well as a several months’ long trial, the High Court rejected all claims against Renault. Renault Group welcomes this decision, which is fully consistent with its long-held position that its vehicles have been and are designed, engineered, and manufactured in accordance with all applicable regulatory requirements. Renault Group will now pursue the recovery of its legal costs from...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.